and nivolumab after the radiation. After clinical deterioration within 4 weeks of starting checkpoint therapy, the patient showed a marked increase in T2 changes outside the radiation field.

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

(Jan. 2 issue), 1 the combination of nivolumab and ipilimumab resulted in an unprecedented increase in overall and melanoma-specific survival, as compared with ipilimumab alone. We should be wary ...

Nivolumab for subcutaneous use co-formulated with recombinant human hyaluronidase (rHuPH20), is indicated across multiple previously approved adult solid tumors as monotherapy, monotherapy ...

SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to ...

Cutaneous vasculitis (CV) is a term used for inflammation of the blood vessels in the skin that occurs in up to 70% of patients with lupus erythematosus (LE). The inflammation affects the smaller ...

There were 11 hypersensitivity reactions, all in patients receiving nivolumab. Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers.

Among the general data from the CheckMate 649 trial (NCT02872116) of nivolumab plus chemotherapy, he touched on the continuing debate of using combined positive score (CPS) of PD-L1 as a cut-off, as ...

umin.ac.jp Nivolumab is a monoclonal antibody to programmed cell death-1 (PD-1) protein and acts as an immune checkpoint inhibitor by disrupting the interaction of the PD-1 receptor with its ligands.